CHO cell: all 35 studies that test it

Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AboveNot yet recruitingNCT07892989Phase 1/2
• Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)RecruitingNCT07860216Phase 3
• Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and OlderNot yet recruitingNCT07807449Phase 1
• A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Not yet recruitingNCT07618325Not applicable
• Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.RecruitingNCT07582796Phase 1/2
• Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)RecruitingNCT07272434Phase 3
• Safety Study of COVID19 Vaccine on the MarketRecruitingNCT05890521Phase 4
• A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)Active, not recruitingNCT07293065Phase 3
• Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and OlderActive, not recruitingNCT06851832Phase 1/2
• Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).CompletedNCT06654700Phase 3
• Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and OlderActive, not recruitingNCT06447779Phase 3
• The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)CompletedNCT05769049Phase 1
• Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or OlderTerminatedNCT05683600Phase 3
• Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and AboveStatus unknownNCT05664932Phase 3
• Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)CompletedNCT05574985Not applicable
• Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)CompletedNCT05398848Phase 3
• Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)CompletedNCT05323435Phase 2
• Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal FailureStatus unknownNCT05211167Phase 3
• Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)Status unknownNCT05128643Phase 3
• Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)CompletedNCT05109598Phase 2
• Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza VaccineCompletedNCT05107375Phase 3
• Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)Status unknownNCT05091411Phase 3
• Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing ImmunityCompletedNCT05089045Not applicable
• Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)CompletedNCT05084989Phase 2
• Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus unknownNCT05033847Phase 2
• Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)CompletedNCT04961359Phase 1
• A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedNCT04869592Phase 1/2
• Safety, Reactogenicity and Immunogenicity Study of ReCOVCompletedNCT04818801Early Phase 1
• Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)Status unknownNCT04813562Phase 2
• A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19Status unknownNCT04646590Phase 3
• Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)Status unknownNCT04636333Phase 1
• Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)Status unknownNCT04550351Phase 1
• Clinical Study of Recombinant Novel Coronavirus VaccineStatus unknownNCT04466085Phase 2
• Phase I Clinical Study of Recombinant Novel Coronavirus VaccineStatus unknownNCT04445194Phase 1
• Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With HemodialysisStatus unknownNCT03950687Phase 2

← CHO cell overview